Extracorporeal Blood Adsorber Product Introduction

1. Extracorporeal Blood Adsorber Product Introduction
The Extracorporeal Blood Adsorber is a device designed to remove specific substances from the patient's blood outside of the body, utilizing a specialized adsorption material that selectively targets and binds to these substances. This process allows for the effective elimination of toxins, drugs, and waste products that may be harmful to the patient's health. The adsorber is engineered to maintain the integrity of the blood cells and plasma, ensuring that only the targeted substances are removed, thus preserving the patient's overall blood composition. The system is highly efficient, enabling rapid treatment and recovery, and is adaptable to various patient conditions, making it a versatile tool in medical care.

Figure1: Extracorporeal Blood Adsorber Product Picture

Extracorporeal Blood Adsorber

Based on or includes research from QYResearch:

2. Leading Manufacturer in the industry
1) Fresenius Medical Care

Fresenius Medical Care is a global medical technology enterprise centered on the treatment of kidney diseases. Its business revolves around providing comprehensive clinical products, services, and solutions for patients with chronic renal failure and other kidney-related diseases. This encompasses hemodialysis machines, peritoneal dialysis systems, disposable medical consumables, infusion solutions and pharmaceuticals, combined with a network of diagnosis and treatment support services to assist hospitals and dialysis centers in optimizing blood purification treatment processes. The company's products are utilized globally in hospitals, dialysis centers, and critical care environments, supporting routines including conventional dialysis, continuous kidney replacement therapy (CKRT), therapeutic plasma exchange, and other extracorporeal blood purification modalities. Concurrently, through clinical collaboration, it strengthens therapy integration and innovation to enhance treatment quality and patient care experience. Official product presentations indicate that its consumables and systems are designed to promote high standards in dialysis and purification therapy and to provide supportive solutions for blood purification applications in acute and critical care.

Regarding extracorporeal hemoperfusion cartridges, Fresenius Medical Care offers different types of perfusion components within its critical care and acute blood purification product portfolio to support extracorporeal blood purification therapies. The company, through partnerships, introduces and distributes resin-based perfusion cartridges such as CytoSorb. This component utilizes porous polymer resin beads to adsorb inflammatory mediators, cytokines, and other middle-molecular-weight substances from the blood during extracorporeal circulation, thereby assisting in controlling severe inflammatory responses and toxic substance accumulation. Simultaneously, Fresenius Medical Care has expanded its portfolio with pathogen adsorption perfusion devices introduced through third-party technology collaborations, such as the Seraph 100 Affinity Adsorption Filter. This device, employing activated carbon or functional surface adsorption materials, removes pathogens from the bloodstream via extracorporeal circulation for auxiliary purification treatment in states of infectious blood diffusion. Furthermore, in certain markets, the company offers composite material perfusion components. These components integrate different adsorption media and membrane technologies to meet complex clinical purification needs, for example, by enhancing middle-molecular substance removal capacity in scenarios like sepsis or high-toxin clearance, and are compatible with its overall purification platforms. The aforementioned resin-based, activated carbon-based, and composite material hemoperfusion cartridges are designed as single-use components, aiming to deliver an efficient and safe operational experience for single-session extracorporeal circulation purification therapies, supporting extracorporeal hemoperfusion treatment in critical care.

CytoSorb® is an extracorporeal hemoperfusion cartridge, a single-use, non-pyrogenic, sterilized medical device, specifically designed as a third-generation blood adsorption device for critically ill patients. Its core consists of highly porous polystyrene-divinylbenzene copolymer beads, with an average particle size of approximately 450 μm and a pore size of 0.8-5 nm, providing an exceptionally large adsorption surface area (approximately 45,000-46,000 m2/300 mL cartridge). It operates via physical adsorption through a direct hemoperfusion mechanism. Adsorption relies on hydrophobic interactions, concentration dependency, and molecular size selectivity (effectively targeting hydrophobic middle-molecular-weight substances

About Us:
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com

This release was published on openPR.